Global

Jul 18, 2017
The Association of the British Pharmaceutical Industry has sought permission for a Judicial Review of the National Institute for Health and Care Excellence’s unpopular changes to tackle drug affordability.
Jul 12, 2017
Branded generics in select emerging markets can offer above-market returns, writes Renaud Savary.
Jun 27, 2017
Lana Sinichkina, Kateryna Oliinyk and Yevgeniya Ocheretko discuss how the recent settlement between Gilead and Ukraine's Ministry of Health could promote earlier market access in the country.
Jun 19, 2017
Pharmaceutical Executive
Last month’s EFPIA and EU Health Council annual conferences highlighted the growing divisions—and resentments—between industry and governments on drug pricing. Reflector reports.
Jun 02, 2017
With the UK's General Election set for June 8, Leela Barham looks what the competing parties are promising for pharma and healthcare
May 23, 2017
In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector.
Apr 24, 2017
The external reference pricing circus has rolled back into town, promising another great European show. The fight-back comes via one of Europe's most obscure bodies, the European Integrated Price Information Database—better known as Euripid.
Apr 10, 2017
Nine months on from the 2016 EFPIA Disclosure Code deadline — requiring all member companies to publish data concerning their transfer-of-value transactions to HCPs — EFPIA's Andrew Powrie-Smith offered an update on media and industry responses.
Mar 06, 2017
The European Commission's latest economic assessment of EU member states does not make for comfortable reading, writes Reflector.
Mar 01, 2017
Leela Barham looks at NICE's new position statement, which seeks to set out more clearly how it works with industry.
native1_300x100
lorem ipsum